(12) found that there were significant dissimilarities in patients with rheumatoid arthritis who tested positive and negative for ANA concerning the duration to satisfy the RA criteria and choice of initial pharmacotherapy. The gene discussed is BTG3; the disease is rheumatoid arthritis.